Follow Us:

SOUTH KOREA

  • Lilly & Hanmi Ink US$690 Million Deal

    Asian Scientist Newsroom | March 26, 2015 | Pharma

    Eli Lilly has acquired Hanmi’s BTK inhibitor HM71224, a small molecule soon to enter Phase II trials for autoimmune diseases.

MORE NEWS FROM South Korea

Subscribe to our newsletter